Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Shares Outstanding (Diluted Average) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $47.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 29.67% to $47.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.7 million through Dec 2025, up 29.67% year-over-year, with the annual reading at $47.7 million for FY2025, 29.67% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $47.7 million at Orchestra BioMed Holdings, down from $52.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $52.2 million in Q3 2025, with the low at $9.2 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $31.4 million, with a median of $34.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 208.03% in 2023, then rose 6.87% in 2025.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $15.0 million in 2022, then surged by 121.67% to $33.2 million in 2023, then rose by 10.82% to $36.8 million in 2024, then rose by 29.67% to $47.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $47.7 million, $52.2 million, and $38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.